Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sugar test reveals hidden metabolic clues in PCOS

NCT ID NCT07687264

Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates how the bodies of women with Polycystic Ovary Syndrome (PCOS) respond to sugar compared to women without the condition. Participants drink a sugary solution, and blood and urine samples are analyzed using advanced technology to track changes in proteins, metabolites, and immune signals. The goal is to better understand the metabolic differences in PCOS, which could lead to improved diagnosis and treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward better diagnostic tools or treatments for PCOS by revealing how metabolism, hormones, and immunity interact.
What could go wrong
This is an observational study with only 40 participants, so findings may not apply to all women with PCOS. It aims to understand mechanisms, not test a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18-35 years * Body weight (BMI): between BMI 18.5-39.9 kg/m2 * Ability to consent and to provide written informed consent * CG: History of regular MCs (21 to 35 days) 3 months prior to study enrollment * PCOS-G: Existing or new established diagnosis of PCOS. Diagnosis is verified in accordance with the ESHRE/ASRM Rotterdam consensus (2003)23, phenotype A (hyperandrogenism, oligo-/anovulation, and polycystic ovarian morphology). PCOS is diagnosed when at least the following three criteria are present, after exclusion of other etiologies: * Oligo- or anovulation * Clinical and/or biochemical signs of hyperandrogenism * Polycystic ovaries on ultrasound (≥12 follicles per ovary measuring 2-9 mm in diameter and/or ovarian volume \>10 mL) Exclusion Criteria: * Use of systemic hormonal contraceptives within the last 3 months prior to study enrollment. Use of levonorgestrel-releasing intrauterine devices is permitted; all other hormonal contraceptive methods are excluded. * CG: A clinically diagnosed or history of a menstrual disorder (e.g., polycystic ovarian syndrome (PCOS), premenstrual dysphoric disorder (PMDD) or amenorrhea) * A clinically diagnosed mental disorder (e.g. major depression, anxiety disorder) * history of epileptic seizure * history of or current manic or psychotic episode * existing/current eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years * inability to communicate adequately in speech * inability to follow instructions * regular use of medication other than thyroxine * alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day * vegan diet * daily nicotine consumption * currently or history of (regular) consumption of illegal drugs within the last year * pregnancy or breastfeeding * known diseases of the cardiovascular system * arterial hypertension above 160/90 mm/Hg at rest * known pulmonary diseases * Arthritis and rheumatic diseases and conditions * Hematologic diseases * surgery less than 1 month ago * having given birth within 12 months before the start of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulinemic response are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation Overweight polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulinemic response Overweight (bmi > 25) PCOS (polycystic ovary syndrome)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Zurich

    Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.